{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:43:32Z","timestamp":1791855812962,"version":"4.3.4"},"reference-count":63,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013317","name":"Shanxi Provincial Key Research and Development Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170722"],"award-info":[{"award-number":["82170722"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.heliyon.2024.e41212","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T12:32:37Z","timestamp":1734093157000},"page":"e41212","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Rituximab-associated adverse events in nephrotic syndrome: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"11","author":[{"given":"Zixian","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlong","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiayin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueru","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8580-9746","authenticated-orcid":false,"given":"Shiren","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.heliyon.2024.e41212_bib1","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1681\/ASN.2020111583","article-title":"Primary nephrotic syndrome and risks of ESKD, cardiovascular events, and death: the kaiser permanente nephrotic syndrome study","volume":"32","author":"Go","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"issue":"10141","key":"10.1016\/j.heliyon.2024.e41212_bib2","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(18)30536-1","article-title":"Idiopathic nephrotic syndrome in children","volume":"392","author":"Noone","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e41212_bib3","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1681\/ASN.V85824","article-title":"Treatment of the idiopathic nephrotic syndrome: regimens and outcomes in children and adults","volume":"8","author":"Tune","year":"1997","journal-title":"J. Am. Soc. Nephrol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e41212_bib4","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s00281-013-0415-3","article-title":"Immunopathogenesis of idiopathic nephrotic syndrome with relapse","volume":"36","author":"Sahali","year":"2014","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.heliyon.2024.e41212_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.823204","article-title":"B-cell dysregulation in idiopathic nephrotic syndrome: what we know and what we need to discover","volume":"13","author":"Colucci","year":"2022","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e41212_bib6","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.autrev.2012.09.002","article-title":"Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases","volume":"12","author":"Kattah","year":"2013","journal-title":"Autoimmun. Rev."},{"issue":"9337","key":"10.1016\/j.heliyon.2024.e41212_bib7","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","article-title":"Rituximab for idiopathic membranous nephropathy","volume":"360","author":"Remuzzi","year":"2002","journal-title":"Lancet."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e41212_bib8","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.2215\/CJN.09421010","article-title":"Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial","volume":"6","author":"Ravani","year":"2011","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e41212_bib9","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1681\/ASN.2012020181","article-title":"Rituximab in idiopathic membranous nephropathy","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e41212_bib10","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e41212_bib11","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","article-title":"Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20","volume":"83","author":"Reff","year":"1994","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e41212_bib12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e41212_bib13","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1053\/j.ajkd.2022.11.012","article-title":"Age of onset and disease course in biopsy-proven minimal change disease: an analysis from the cure glomerulonephropathy network","volume":"81","author":"Chen","year":"2023","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.heliyon.2024.e41212_bib14","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2021.728010","article-title":"The efficacy and safety of rituximab for childhood steroid-dependent nephrotic syndrome: a systematic review and meta-analysis","volume":"9","author":"Liu","year":"2021","journal-title":"Front Pediatr"},{"issue":"22","key":"10.1016\/j.heliyon.2024.e41212_bib15","first-page":"8021","article-title":"Efficacy and safety of rituximab therapy for membranous nephropathy: a meta-analysis","volume":"22","author":"Zhang","year":"2018","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"10.1016\/j.heliyon.2024.e41212_bib16","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.2020071091","article-title":"Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial","author":"Scolari","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"issue":"46","key":"10.1016\/j.heliyon.2024.e41212_bib17","article-title":"Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: a multicenter open-label trial in Korea","volume":"97","author":"Ahn","year":"2018","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.heliyon.2024.e41212_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.heliyon.2024.e41212_bib19","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"18","author":"Higgins","year":"2011","journal-title":"Bmj-Brit Med J"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e41212_bib20","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur. J. Epidemiol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e41212_bib21","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","article-title":"Assessing heterogeneity in meta-analysis: Q statistic or I2 index?","volume":"11","author":"Huedo-Medina","year":"2006","journal-title":"Psychol. Methods"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e41212_bib22","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.kint.2020.10.014","article-title":"The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy","volume":"99","author":"Fernandez-Juarez","year":"2021","journal-title":"Kidney Int."},{"key":"10.1016\/j.heliyon.2024.e41212_bib23","doi-asserted-by":"crossref","DOI":"10.1007\/s00467-022-05475-8","article-title":"Efficacy of rituximab versus tacrolimus in difficult-to-treat steroid-sensitive nephrotic syndrome: an open-label pilot randomized controlled trial","author":"Mathew","year":"2022","journal-title":"Pediatr. Nephrol."},{"issue":"9950","key":"10.1016\/j.heliyon.2024.e41212_bib24","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","article-title":"Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial","volume":"384","author":"Iijima","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e41212_bib25","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e41212_bib26","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1001\/jamapediatrics.2018.1323","article-title":"Efficacy of rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: a randomized clinical trial","volume":"172","author":"Basu","year":"2018","journal-title":"JAMA Pediatr."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e41212_bib27","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1681\/ASN.2021040561","article-title":"Human or chimeric monoclonal anti-CD20 antibodies for children with nephrotic syndrome: a superiority randomized trial","volume":"32","author":"Ravani","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.heliyon.2024.e41212_bib28","unstructured":"INVALID CITATION !!! ."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e41212_bib29","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1681\/ASN.2016091022","article-title":"Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy","volume":"28","author":"van den Brand","year":"2017","journal-title":"J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e41212_bib30","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/bcp.13548","article-title":"Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome","volume":"84","author":"Bonanni","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e41212_bib31","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40259-017-0221-x","article-title":"Rituximab for steroid-dependent or frequently relapsing idiopathic nephrotic syndrome in adults: a retrospective, multicenter study in Spain","volume":"31","author":"DaSilva","year":"2017","journal-title":"BioDrugs"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e41212_bib32","first-page":"7622","article-title":"Combination of ultra-low dose rituximab and low dose tacrolimus versus tacrolimus alone in the treatment of non-responsive idiopathic membranous nephropathy: a Chinese retrospective cohort study","volume":"13","author":"Zhu","year":"2021","journal-title":"Am J Transl Res"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e41212_bib33","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00467-011-1997-4","article-title":"Short-term efficacy of rituximab versus tacrolimus in steroid-dependent nephrotic syndrome","volume":"27","author":"Sinha","year":"2012","journal-title":"Pediatr. Nephrol."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e41212_bib34","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.medcli.2020.07.039","article-title":"Efficacy and safety of rituximab for childhood refractory nephrotic syndrome: a meta-analysis of randomized controlled trials","volume":"157","author":"Chang","year":"2021","journal-title":"Med. Clin."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e41212_bib35","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.nephro.2021.10.002","article-title":"Evaluation of efficacy of rituximab for membranous nephropathy: a systematic review and meta-analysis of 11 studies","volume":"18","author":"Ou","year":"2022","journal-title":"Nephrol Ther"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e41212_bib36","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12882-020-01797-7","article-title":"Rituximab therapy for focal segmental glomerulosclerosis and minimal change disease in adults: a systematic review and meta-analysis","volume":"21","author":"Hansrivijit","year":"2020","journal-title":"BMC Nephrol."},{"issue":"3\u20134","key":"10.1016\/j.heliyon.2024.e41212_bib37","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1159\/000368589","article-title":"Rituximab in primary membranous nephropathy: first-line therapy, why not?","volume":"128","author":"Cravedi","year":"2014","journal-title":"Nephron Clin. Pract."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e41212_bib38","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(21)00167-8","article-title":"Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on Adverse Reactions","volume":"8","author":"Bennett","year":"2021","journal-title":"The Lancet Haematology"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e41212_bib39","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1007\/s00467-009-1195-9","article-title":"Fatal pulmonary fibrosis after rituximab administration","volume":"24","author":"Chaumais","year":"2009","journal-title":"Pediatr. Nephrol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e41212_bib40","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.autrev.2017.04.007","article-title":"Rituximab for immunologic renal disease: what the nephrologist needs to know","volume":"16","author":"Kronbichler","year":"2017","journal-title":"Autoimmun. Rev."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e41212_bib41","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/ejhpharm-2017-001454","article-title":"Tolerance and safety of rapid 2-hour infusion of rituximab in patients with kidney-affecting autoimmune diseases and glomerulonephritides: a single-centre experience","volume":"26","author":"Hartinger","year":"2019","journal-title":"Eur. J. Hosp. Pharm."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e41212_bib42","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/1744666X.2019.1562905","article-title":"Infusion-related reactions to rituximab: frequency, mechanisms and predictors","volume":"15","author":"Paul","year":"2019","journal-title":"Expert Rev Clin Immunol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e41212_bib43","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s40259-021-00487-6","article-title":"Factors influencing infusion-related reactions following dosing of reference rituximab and PF-05280586, a rituximab biosimilar","volume":"35","author":"Courville","year":"2021","journal-title":"BioDrugs"},{"key":"10.1016\/j.heliyon.2024.e41212_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.572863","article-title":"Rituximab hypersensitivity: from clinical presentation to management","volume":"11","author":"Fouda","year":"2020","journal-title":"Front. Pharmacol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e41212_bib45","doi-asserted-by":"crossref","first-page":"932","DOI":"10.2215\/CJN.01180307","article-title":"Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy","volume":"2","author":"Cravedi","year":"2007","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e41212_bib46","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1634\/theoncologist.2008-0012","article-title":"Managing premedications and the risk for reactions to infusional monoclonal antibody therapy","volume":"13","author":"Chung","year":"2008","journal-title":"Oncol."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e41212_bib47","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.2215\/CJN.01920218","article-title":"Complications of immunosuppression in glomerular disease","volume":"13","author":"Jefferson","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e41212_bib48","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1681\/ASN.2021111472","article-title":"Long-term efficacy and safety of repeated rituximab to maintain remission in idiopathic childhood nephrotic syndrome: an international study","volume":"33","author":"Chan","year":"2022","journal-title":"J. Am. Soc. Nephrol."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e41212_bib49","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1080\/08830185.2017.1346092","article-title":"Risk factors predisposing to the development of hypogammaglobulinemia and infections post-Rituximab","volume":"36","author":"Christou","year":"2017","journal-title":"Int. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e41212_bib50","first-page":"461","article-title":"Infectious complications of a rituximab-based immunosuppressive regimen in patients with glomerular disease","volume":"10","author":"Trivin","year":"2017","journal-title":"Clinical kidney journal"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e41212_bib51","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1681\/ASN.2007020166","article-title":"A randomized, controlled trial of steroids and cyclophosphamide in adults with nephrotic syndrome caused by idiopathic membranous nephropathy","volume":"18","author":"Jha","year":"2007","journal-title":"J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e41212_bib52","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1159\/000437287","article-title":"Management of membranous nephropathy in western countries","volume":"1","author":"Alfaadhel","year":"2015","journal-title":"Kidney Dis."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e41212_bib53","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1179\/1973947815Y.0000000025","article-title":"Severe and fatal adverse events risk associated with rituximab addition to B-cell non-Hodgkin's lymphoma (B-NHL) chemotherapy: a meta-analysis","volume":"27","author":"Hua","year":"2015","journal-title":"J. Chemother."},{"issue":"13","key":"10.1016\/j.heliyon.2024.e41212_bib54","first-page":"2589","article-title":"Therapeutic targeting of inflammation in hypertension: from novel mechanisms to translational perspective","volume":"117","author":"Murray","year":"2021","journal-title":"Cardiovasc. Res."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e41212_bib55","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s11523-015-0368-7","article-title":"Renal toxicities of targeted therapies","volume":"10","author":"Abbas","year":"2015","journal-title":"Target Oncol"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e41212_bib56","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/COC.0000000000000553","article-title":"Clinical features of rituximab-associated gastrointestinal toxicities","volume":"42","author":"Mallepally","year":"2019","journal-title":"Am. J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e41212_bib57","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2169\/internalmedicine.5119-20","article-title":"Rituximab-induced ileocolitis in a patient with gastric MALToma: a case report and literature review","volume":"60","author":"Tsuzuki","year":"2021","journal-title":"Intern Med"},{"key":"10.1016\/j.heliyon.2024.e41212_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.645500","article-title":"Lactobacillus reuteri alleviates gastrointestinal toxicity of rituximab by regulating the proinflammatory T cells in vivo","volume":"12","author":"Zhao","year":"2021","journal-title":"Front. Microbiol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e41212_bib59","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/jdv.12622","article-title":"Novel presentation of rituximab-induced herpes zoster: urinary retention and acute kidney failure","volume":"30","author":"Diernaes","year":"2016","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e41212_bib60","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/ajh.10213","article-title":"Treatment of a patient with end-stage renal disease with Rituximab: pharmacokinetic evaluation suggests Rituximab is not eliminated by hemodialysis","volume":"71","author":"Jillella","year":"2002","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e41212_bib61","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijcard.2010.03.003","article-title":"Cardiac side-effects of cancer chemotherapy","volume":"144","author":"Monsuez","year":"2010","journal-title":"Int. J. Cardiol."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e41212_bib62","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1136\/annrheumdis-2012-201956","article-title":"Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients","volume":"72","author":"van Vollenhoven","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e41212_bib63","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1053\/j.ajkd.2021.04.014","article-title":"Combination of rituximab, low-dose cyclophosphamide, and prednisone for primary membranous nephropathy: a case series with extended follow up","volume":"78","author":"Zonozi","year":"2021","journal-title":"Am. J. Kidney Dis."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402417243X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S240584402417243X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T21:19:36Z","timestamp":1776374376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S240584402417243X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S240584402417243X"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e41212","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab-associated adverse events in nephrotic syndrome: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e41212","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e41212"}}